Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Neurological Devices Panel of the Medical Devices Advisory Committee. This meeting was announced in the Federal Register of February 7, 2011 (76 FR 6625). The amendment is being Start Printed Page 12974made to reflect a change in the Agenda portion of the document. There are no other changes.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Olga I. Claudio, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1611, Silver Spring, MD 20993-0002, 301-796-7608, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.End Further Info End Preamble Start Supplemental Information
In the Federal Register of February 7, 2011, FDA announced that a meeting of the Neurological Devices Panel of the Medical Devices Advisory Committee would be held on March 17 and 18, 2011. On page 6625, in the second column, in the last paragraph, in the first and second sentences, the “for the NovoTTF-100A Treatment Kit, sponsored by Hogan Lovells US LLP for NovoCure, Ltd. The NovoTTF-100A Treatment Kit” portion of the document is changed to read as follows: “for the NovoTTF-100A System, sponsored by NovoCure, Ltd. The NovoTTF-100A System”.
This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.Start Signature
Dated: March 3, 2011.
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-5285 Filed 3-8-11; 8:45 am]
BILLING CODE 4160-01-P